Alector Inc
(STU:0Z2)
€
3.98
-0.02 (-0.5%)
Market Cap: 391.41 Mil
Enterprise Value: -93.80 Mil
PE Ratio: 0
PB Ratio: 2.37
GF Score: 62/100 - Q4 2023 Alector Inc Earnings Call TranscriptFeb 27, 2024€5.85 (+1.74%)Earnings
- Alector Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Q2 2023 Alector Inc Earnings Call TranscriptAug 03, 2023€6 (-1.64%)Earnings
- Alector Inc at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- H.C. Wainwright with Alector TranscriptMay 24, 2023
- Alector Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Alector Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2022
- Alector Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- Alector Inc at Bank of America Healthcare Conference TranscriptMay 12, 2022
- Alector Inc at Stifel CNS Days (Virtual) TranscriptMar 28, 2022
- Alector Inc at Barclays Global Healthcare Conference TranscriptMar 16, 2022
- Alector Inc to Present New AL001 Data- Conference Call TranscriptMar 15, 2022
- Ultragenyx Pharmaceutical Inc, Alector Inc, Passage Bio Inc, AVROBIO Inc and Annexon Inc in the Orphan CNS Panel at Cowen Health Care Conference (Virtual) TranscriptMar 08, 2022
- Alector Inc to Present to Discuss Data Presented at 2021 Clinical Trials on Alzheimer's Disease Meeting TranscriptNov 12, 2021
- Alector Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 13, 2021
- Alector Inc at Citi BioPharma Conference (Virtual)- Panel: What's Next for Neurodegenerative Diseases TranscriptSep 08, 2021
- Alector Inc to Review the AL001 Phase 2 Results- Conference Call TranscriptJul 29, 2021
- Alector Inc to Discuss Collaboration with GlaxoSmithKline PLC for AL001 & AL101 Call TranscriptJul 02, 2021
- Alector Inc at Bank of America NAPA Healthcare Conference TranscriptJun 14, 2021
- Alector Inc to Host Virtual Key Opinion Leader Event on Frontotemporal Dementia TranscriptJun 11, 2021
- Alector Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Alector Inc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 13, 2021
- Alector Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 11, 2021
- Alector Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2020
- Alector Inc at Citi BioPharma Conference (Virtual) TranscriptSep 10, 2020
- Alector Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2020
- Alector Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 13, 2020
- Alector Inc at JPMorgan Healthcare Conference TranscriptJan 16, 2020
- Alector, Inc. - Special Call TranscriptDec 13, 2019
- Alector Inc at Morgan Stanley Healthcare Conference TranscriptSep 10, 2019
- Alector Inc at Bank of America Merrill Lynch Health Care Conference TranscriptMay 15, 2019
Alector Inc at Bank of America NAPA Healthcare Conference Transcript
Jun 14, 2021 / 09:30PM GMT
Release Date Price:
€15.9
(+1.92%)
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
Okay. Welcome to the afternoon sessions of the Second Annual Virtual Napa conference. Next here will be the real thing. Fingers crossed. My name is Geoff Meacham, I'm the senior biopharma analyst here, and I have Alex Hammond from my team with me as well. And we're thrilled to have Alector with us for this last session and speaking on behalf of Alector is President and COO, Shehnaaz Suliman. How are you doing, Shehnaaz? It's good to see you.
Shehnaaz Suliman
Alector, Inc. - President, COO & Interim Chief Business Officer
Doing great. Thanks for having us.
Questions & Answers
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
Yes. So we'll start it off with maybe just sort of a recap of the events of early last week with Biogen's aducanumab obviously, doesn't directly affect you, but I wanted to kind of get your thoughts of the FDA decision and maybe what that means for Alzheimer's or
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)